Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting

Background Data on eribulin as the first- or second-line treatment in a clinical setting, especially the overall survival (OS) of patients, are scarce. Therefore, we assessed the effectiveness and safety of eribulin as the first-, second-, and third- or later-line treatments in patients with human e...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Kenichi, Takahashi, Masato, Mukai, Hirofumi, Yamanaka, Takashi, Egawa, Chiyomi, Sakata, Yukinori, Ikezawa, Hiroki, Matsuoka, Toshiyuki, Tsurutani, Junji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Phase II Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497681/
https://www.ncbi.nlm.nih.gov/pubmed/31950374
http://dx.doi.org/10.1007/s10637-019-00890-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497681/
https://www.ncbi.nlm.nih.gov/pubmed/31950374
http://dx.doi.org/10.1007/s10637-019-00890-5

Ejemplares similares